Article
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.
Leukemia - 1 Jan 2026
Bill Marius, Eckardt Jan-Niklas, Döhner Konstanze, Röhnert Maximillian-Alexander, Rausch Christian, Metzeler Klaus H, Spiekermann Karsten, Stasik Sebastian, Wurm Alexander A, Sauer Tim, Scholl Sebastian, Schnetzke Ulf, Hochhaus Andreas, Crysandt Martina, Brümmendorf Tim H, Krug Utz, Wörmann Bernhard, Einsele Hermann, Hiddemann Wolfgang, Görlich Dennis, Sauerland Cristina, Steffen Björn, Neubauer Andreas, Burchert Andreas, Schäfer-Eckart Kerstin, Berdel Wolfgang E, Schliemann Christoph, Krause Stefan W, Hänel Mathias, Hanoun Maher, Kaufmann Martin, Fransecky Lars, Braess Jan, Schetelig Johannes, Middeke Jan Moritz, Bullinger Lars, Heuser Michael, Thol Felicitas, Serve Hubert, Baldus Claudia D, Platzbecker Uwe, Müller-Tidow Carsten, Válka Jan, Šrámek Jiří, Weinbergerova Barbora, Mayer Jiri, Dumas Pierre-Yves, Bertoli Sarah, Delabesse Eric, Récher Christian, Pigneux Arnaud, Herold Tobias, Ganser Arnold, Döhner Hartmut, Bornhäuser Martin, Thiede Christian, Röllig Christoph
Abstract excerpt
In the European LeukemiaNet (ELN) 2022 recommendations, myelodysplasia-related (MR) gene mutations were classified as a novel adverse prognostic category for intensively treated acute myeloid leukemia (AML). To assess the prognostic impact of individual MR genes within the ELN, clinical, cytogenetic, and molecular data from 4,978 intensively treated AML patients were analyzed. Remission rates and survival...
Read the complete abstract on PubMed